Ten analysts set USD 12.00 target for Replimune stock

Published on 10/17/2026 at 22:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

June 2026 loss was USD 0.72 per share versus USD 0.69 expected. Replimune stock closed at USD 10.86 on October 16, 2026, down 7.57 percent on Nasdaq.

Analyst targets and earnings date

MarketBeat reported a USD 12.00 average target from ten ratings firms on October 13, 2026.
Replimune lost USD 0.72 per share in the quarter ended June 30, 2026, versus USD 0.69 expected.
Replimune stock closed at USD 10.86 on Nasdaq on October 16, 2026, down 7.57 percent on the day.
The next estimated earnings date is November 5, 2026.

REPL, US76029N1063, Illustration mit AI erstellt.

On October 13, 2026, MarketBeat reported a Moderate Buy consensus from ten ratings firms and an average 12-month target of USD 12.00. That target is 10.50 percent above the Nasdaq closing price of October 16, 2026. Replimune stock closed at USD 10.86 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 7.57 percent from its prior close.

Quarterly loss sets the backdrop

MarketBeat said Replimune reported a loss of USD 0.72 per share for the quarter ended June 30, 2026, missing the USD 0.69 consensus estimate by USD 0.03. The result gives the analyst target a more demanding backdrop because the company is still funding clinical development while commercializing its cancer therapy portfolio.

Replimune describes its RPx platform as a foundation for oncolytic immunotherapies that use an HSV-1 backbone to kill tumor cells and stimulate a systemic immune response, according to the company's Replimune investor-relations page.

Trading range remains wide

The October 16 close stood within a 52-week range of USD 1.50 to USD 16.33. Trading volume reached 1,710,753 shares against an average of 4,041,181 shares, while the market capitalization was USD 1.0 billion. The price therefore sat USD 5.47 below the 52-week high, a 33.50 percent gap calculated from the high.

Valuation and next date

Replimune carried a trailing P/E ratio of minus 3.45 on October 17, 2026. The next estimated earnings date is November 5, 2026, before the market opens, according to MarketBeat. The page also lists an expected loss of USD 0.7840 per share and revenue of USD 1.00 million for the coming quarter.

Comparison with peers

Replimune (Nasdaq, USD): minus 7.57 percent, P/E minus 3.45, market capitalization USD 1.0 billion.

Iovance Biotherapeutics (Nasdaq, USD): minus 7.47 percent, P/E minus 18.66, market capitalization USD 6.2 billion.

TG Therapeutics (Nasdaq, USD): minus 3.62 percent, P/E 19.70, market capitalization USD 8.3 billion.

Price and investor dates

Replimune's October 16 decline came alongside a weaker session for both selected biotechnology peers, with Iovance falling 7.47 percent and TG Therapeutics declining 3.62 percent. The company remains tied to clinical execution and upcoming reporting milestones rather than a positive earnings base.

Replimune stock closed at USD 10.86 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 7.57 percent from its prior close.